Tirzepatide 10 mg

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Beligas - US
WAREHOUSE USA Warehouse 2
SUBSTANCE GIP/GLP-1 RA

Introducing **Tirzepatide**, a groundbreaking synthetic peptide designed to effectively lower glucose levels in individuals with type 2 diabetes. This innovative treatment works by enhancing both first- and second-phase insulin secretion while simultaneously reducing glucagon levels, all in a glucose-dependent manner.

Clinical studies reveal that Tirzepatide can significantly slow gastric emptying, leading to lower fasting and post-meal glucose levels. Additionally, it reduces appetite and supports weight loss, making it a powerful ally in diabetes management. Tirzepatide also has the potential to improve insulin sensitivity, further optimizing glucose control.

This peptide is uniquely structured with a C20 fatty diacid linked through a hydrophilic connector at the lysine residue in position 20, ensuring robust binding to plasma albumin and extending its active half-life to an impressive 5 days.

Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are prevalent throughout the body, particularly in pancreatic beta-cells and the gastrointestinal tract. These receptors play a vital role in glucose regulation, promoting increased insulin secretion, slowing gastric transit, and reducing plasma glucagon levels. They also influence appetite and weight loss pathways in the brain. Alongside GLP-1, glucose-dependent insulinotropic polypeptide (GIP) assists in maintaining glucose homeostasis by stimulating insulin production from pancreatic beta-cells, especially in response to food intake.

While the exact mechanism of Tirzepatide remains partially understood, its dual action on GIP and GLP-1R appears crucial for effective glycemic control and weight management. Research indicates that combining GIP with a GLP-1R agonist yields a more pronounced insulin response and a greater suppression of glucagon than either hormone alone. Tirzepatide exhibits a high binding affinity for both GIP and GLP-1R, demonstrating a receptor affinity for GIP similar to that of native GIP, although it is five times less effective at binding GLP-1R compared to native GLP-1. It effectively activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion via either GIP receptor (GIPR) or GLP-1R. However, ongoing research is essential to further clarify how GIPR activation influences Tirzepatide's role in glycemic control and weight management, as current evidence from clinical and preclinical studies shows some variability.